🇺🇸 FDA
Pipeline program

MBX 1416 (Part A)

MBX-1P2001

Phase 1 small_molecule completed

Quick answer

MBX 1416 (Part A) for Postbariatric Hypoglycemia is a Phase 1 program (small_molecule) at MBX Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
MBX Biosciences
Indication
Postbariatric Hypoglycemia
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials